The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 24, 2020

Filed:

Jan. 11, 2017
Applicants:

Samjin Pharmaceutical Co., Ltd., Seoul, KR;

Incheon Univeristy Industry Academic Cooperation Foundation, Incheon, KR;

Bamichem Co., Ltd., Incheon, KR;

Inventors:

Eui Hwan Cho, Seoul, KR;

Hee Jong Shin, Gyeonggi-do, KR;

Min Hyo Ki, Gyeonggi-do, KR;

Ho Seok Kwon, Gyeonggi-do, KR;

Jae Woong Lee, Gyeonggi-do, KR;

Jeong Ho Joo, Gyeonggi-do, KR;

Keun Kuk Lee, Gyeonggi-do, KR;

Jong Min Kim, Seoul, KR;

Yong Bin Park, Gyeonggi-do, KR;

Sung Hyun Kang, Seoul, KR;

Hyoung Min Cho, Gyeonggi-do, KR;

Hyun Tae Kim, Gyeonggi-do, KR;

Soon Kil Ahn, Seoul, KR;

Sung Pyo Hong, Gyeonggi-do, KR;

Sung Hye Kim, Gyeonggi-do, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 473/00 (2006.01); A61P 35/00 (2006.01); C07D 487/04 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); A61K 31/52 (2006.01); A61K 31/519 (2006.01);
U.S. Cl.
CPC ...
C07D 473/00 (2013.01); A61K 31/519 (2013.01); A61K 31/52 (2013.01); A61P 35/00 (2018.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 487/04 (2013.01);
Abstract

The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.


Find Patent Forward Citations

Loading…